Prognostic value of myocardial perfusion imaging in asymptomatic high-risk diabetic patients: 10-year follow-up of the prospective multicentre BARDOT trial
Main finding · All-cause mortalityResult — go to the resultHazard ratio 1.614Authors' conclusion
A normal SPECT was associated with an excellent long-term prognosis in high-risk T2DM patients. Hence, SPECT could serve as a valuable tool for advanced risk stratification in this population.
Study context
- Population
- Asymptomatic high-risk T2DM patients without history of coronary artery disease (CAD) screened with SPECT
- Participants
- 400 patients
- Exposure
- Abnormal vs normal SPECT
Methodological details10-year follow-up
- 10-year follow-up
Main finding
All-cause mortality · Median follow-up 11.1 (8.8, 12.8) years
Hazard ratio
1.614
P = 0.029
As reported in the abstract
Observational data: associations, not effects.
Further findings
| Outcome | Abnormal SPECT | Normal SPECT | HR | P value |
|---|---|---|---|---|
| MACE (cardiovascular mortality + myocardial infarction) · Median follow-up 11.1 (8.8, 12.8) years · higher with abnormal SPECT | 2.024 | P = 0.009 | ||
| Annual event rates, normal vs abnormal SPECT | ||||
| All-cause mortality | 3.1%/year | 1.9 | ||
| MACE | 2.3%/year | 1.2 |
- Annual event rates, normal vs abnormal SPECT: all-cause mortality P = 0.016
- Annual event rates, normal vs abnormal SPECT: MACE P = 0.010
Baseline characteristics
- Mean age
- 63 ± 8 years
- Male
- 69%
- Diabetic end-organ damage
- 87%
- Abnormal baseline SPECT
- 22%
Event-free survival by treatment strategy (revascularization vs. conservative) in abnormal SPECT subgroup
- No effect of treatment strategy on event-free survival
- Small subgroup
Original publication
Prognostic value of myocardial perfusion imaging in asymptomatic high-risk diabetic patients: 10-year follow-up of the prospective multicentre BARDOT trial. Eur Heart J Cardiovasc Imaging. Published 23 April 2025. doi:10.
Summarised from the published abstract; every number is checked against it